749269-74-7

Basic information

• Product Name: 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid
• Synonyms: 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid;1-(4-BroMo-3-fluorophenyl)cyclopropanecarboxylic acid
• CAS NO: 749269-74-7
• Molecular Formula: C₁₀H₈BrFO₂
• Molecular Weight: 259.0717232
• Mol File: 749269-74-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid(749269-74-7)
• EPA Substance Registry System: 1-(4-BroMo-3-fluorophenyl)cyclopropane-1-carboxylic acid(749269-74-7)

Safety Data

• Hazardous Substances Data: 749269-74-7(Hazardous Substances Data)

Usage

Description

1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is a chemical compound characterized by a cyclopropane ring fused to a carboxylic acid group and a phenyl ring substituted with bromine and fluorine atoms. This unique structure positions it for various applications in organic chemistry, particularly in research and experimental settings.

Uses

Used in Organic Chemistry Research:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid serves as a valuable compound in organic chemistry research, where it is utilized for the study of cyclopropane-containing compounds and their reactions. Its distinct structural features make it a candidate for exploring novel chemical pathways and mechanisms.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is used as a building block or intermediate in the synthesis of new drugs. Its bromine and fluorine substituents can be leveraged to modulate the compound's properties, potentially enhancing its pharmacological activity and selectivity.
Used in Drug Synthesis:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is employed as a key intermediate in the synthesis of complex organic molecules, including pharmaceutical agents. Its reactivity and functional groups can be exploited in various synthetic routes to construct diverse drug candidates with potential therapeutic applications.
Used in the Study of Cyclopropane-Containing Compounds:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is utilized in the investigation of cyclopropane-containing compounds, which are known for their unique properties and applications in various fields. Research on this compound can provide insights into the behavior and potential uses of cyclopropane derivatives in chemistry and medicine.

Upstream product

• 452-74-4 4-bromo-3-fluorotoluene 
• 942282-41-9 methyl 2-(4-bromo-3-fluorophenyl)acetate 
• 942282-40-8 2-(4-bromo-3-fluorophenyl)acetic acid 
• 499983-13-0 2-( 4-bromo-3-fluorophenyl)acetonitrile 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 
• 749269-73-6 1-(4-bromo-3-fluorophenyl)cyclopropane-1-carbonitrile 

Downstream Products

• 1187369-08-9 [1-(4-bromo-3-fluoro-phenyl)-cyclopropyl]-carbamic acid tert-butyl ester 
• 1279100-76-3 1-(2,4'-difluorobiphenyl-4-yl)cyclopropanecarboxylic acid 
• 1279101-06-2 2-(nitrooxy)ethyl 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279101-03-9 2-(nitrooxy)ethyl 1-(2-fluoro-4'-(trifluoromethyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-99-0 2-(nitrooxy)ethyl 1-(2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-97-8 2-bromoethyl 1-(3',4'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-93-4 2-bromoethyl 1-(2-fluoro-4'-(trifluoromethyl)biphenyl-4-yl)cyclopropanecarboxylate 
• 1279100-92-3 2-bromoethyl 1-(2-fluorobiphenyl-4-yl)cyclopropanecarboxylate 
• 1268445-07-3 (4R)-1-{[1-(4-bromo-3-fluorophenyl)cyclopropyl]carbonyl}-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1268444-93-4 (4R)-1-{[1-(4-bromo-3-fluorophenyl)cyclopropyl]carbonyl}-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-L-prolinamide 
• 865360-51-6 1-(4'-bromo-2,3'-difluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid 

Relevant articles and documents

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates

Poor blood-brain barrier penetration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been blamed for the failure of the selective amyloid lowering agent (SALA) R-flurbiprofen in phase 3 clinical trials for Alzheimer's disease (AD). NO-donor NSAIDs (NO-NSAIDs) provide an alternative, gastric-sparing approach to NSAID SALAs, which may improve bioavailability. NSAID analogues were studied for anti-inflammatory activity and for SALA activity in N2a neuronal cells transfected with human amyloid precursor protein (APP). Flurbiprofen (1) analogues were obtained with enhanced anti-inflammatory and antiamyloidogenic properties compared to 1, however, esterification led to elevated A 1-42 levels. Hybrid nitrate prodrugs possessed superior anti-inflammatory activity and reduced toxicity relative to the parent NSAIDs, including clinical candidate CHF5074. Although hybrid nitrates elevated A 1-42 at higher concentration, SALA activity was observed at low concentrations (1 μM): both A1-42 and the ratio of A 42/A1-40 were lowered. This biphasic SALA activity was attributed to the intact nitrate drug. For several compounds, the selective modulation of amyloidogenesis was tested using an immunoprecipitation MALDI-TOF approach. These data support the development of NO-NSAIDs as an alternative approach toward a clinically useful SALA.